A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
NCT ID: NCT01656525
Last Updated: 2014-09-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2012-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
NCT02051608
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
NCT03443973
An Efficacy and Safety Study of Galantamine for the Treatment of Patients With Alzheimer's Disease
NCT00814801
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
NCT05256134
Safety and Efficacy of MT-4666
NCT01764243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Gantenerumab
75 mg subcutaneous doses every 4 weeks for 24 weeks
2
Gantenerumab
105 mg subcutaneous doses every 4 weeks for 24 weeks
3
Gantenerumab
225 mg subcutaneous doses every 4 weeks for 24 weeks
4
Placebo
subcutaneous doses every 4 weeks for 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gantenerumab
75 mg subcutaneous doses every 4 weeks for 24 weeks
Gantenerumab
105 mg subcutaneous doses every 4 weeks for 24 weeks
Gantenerumab
225 mg subcutaneous doses every 4 weeks for 24 weeks
Placebo
subcutaneous doses every 4 weeks for 24 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet DSM-IV criteria for Dementia of the Alzheimer type
* MMSE score : 16 to 26 etc.
Exclusion Criteria
etc.
50 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chugai Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kansai region
Kansai, , Japan
Kanto region,
Kanto, , Japan
Kyushu region
Kyushu, , Japan
Tokai region
Toakai, , Japan
Tohoku region
Tōhoku, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JapicCTI-121849
Identifier Type: REGISTRY
Identifier Source: secondary_id
JP22431
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.